NEW YORK (Reuters) - Drug makers are calling for steady leadership, political independence and a boost in funding to improve the climate at the U.S. Food and Drug Administration under President-elect Barack Obama. The FDA has suffered with high ...
Read more...
NEW YORK, Nov 21 (Reuters) - Drug makers are calling for steady leadership, political independence and a boost in funding to improve the climate at the U.S. Food and Drug Administration under President-elect Barack Obama. The FDA has suffered with ...
Read more...
(RTTNews) - Dogged by patent expirations, regulatory setbacks and high-profile drug trial failures, 2008 has been a whirlwind year for Pfizer. The drug titan is seeking to cure its ills with serious retrenching measures and by shifting its research ...
Read more...
The agency is thinking about how to weigh such possible side effects as more drugs that treat diabetes, pain and other conditions also appear linked to heart attacks and other complications, Dr. John Jenkins, director of the FDA's Office of New Drugs ...
Read more...
NEW YORK (Reuters) - The rise of serious heart risks in drugs that treat chronic conditions has become one of the U.S. Food and Drug Administration's top worries and is changing how the agency weighs new medicines, a top FDA official said on Tuesday ...
Read more...
NEW YORK— Fitch Ratings Service lowered its rating outlook on Merck and Co.'s debt to "Negative" Monday, citing the potential for greater generic competition for some of the company's best-selling drugs. Fitch cut its rating on Merck's $6.93 ...
Read more...
NEW YORK— In a Nov. 17 story about Merck and Co. , The Associated Press erroneously reported the results of a clinical trial involving Merck's cholesterol drug Vytorin. The trial showed that Vytorin was no better than a generic drug at preventing ...
Read more...